Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents

Steven D. Douglas, Bret Rudy, Larry Muenz, Anna Barbara Moscicki, Craig M. Wilson, Christie Holland, Peggy Crowley-Nowick, Sten H. Vermund, L. Friedman, L. Pall, Donna C. Futterman, D. Monte, M. Alovera-DeBellis, Neal D. Hoffman, B. Rudy, D. Schwarz, M. Tanney, M. Belzer, D. Tucker, L. D'Angelo & 52 others C. Trexler, C. Townsend-Akpan, R. Hagler, L. Peralta, G. Ryder, S. Miller, K. Feroli, S. E. Abdalian, D. Foxworth, L. Green, M. Sturdevant, A. Howell, P. Flynn, K. Lett, A. Puga, Cruz, L. Henry-Reid, R. Camacho, M. Bell, J. Martinez, D. Johnson, L. Levin, M. Geiger, M. Sawyer, G. Walls, J. Birnbaum, M. Ramnarine, P. Stanford, F. Briggs, C. Holland, A. B. Moscicki, D. Murphy, S. H. Vermund, R. Booth, P. Crowley-Nowick, S. D. Douglas, C. M. Wilson, C. Partlow, B. Hobbs, J. Ellenberg, L. Paolinelli, L. Muenz, T. Myers, A. Sheon, Rick Mitchell, A. Rogers, A. Willoughby, K. Davenny, V. Smeriglio, F. Matzen, J. Lew, G. Weissman

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective: To examine potential hematologic and immunologic markers for healthy adolescents and for adolescents infected with HIV. Design: The REACH Project (Reaching for Excellence in Adolescent Care and Health) of the Adolescent Medicine HIV/AIDS Research Network (AMHARN) recruits HIV-infected and high-risk HIV-uninfected adolescents, aged at least 13 but less than 19 years. The study evaluates biomedical and behavioral features of HIV infection as observed while under medical care for HIV infection and adolescent health. Methods: Blood samples were collected from HIV-infected and HIV-uninfected subjects at 16 clinical sites. Cell phenotypes were determined using standard single, dual or three-color flow cytometry. Results: This report includes data at enrollment for 94 HIV-positive adolescents who had never received antiretroviral therapy (ART) (mean age, 17.4 ± 1.0 years for males and 16.5 ± 1.3 years for females) and 149 HIV-negative adolescents (mean age, 16.7 ± 1.2 years for males and 16.6 ± 1.2 years for females); this is the antiretroviral therapy-naive subset drawn from 294 HIV-positive and 149 HIV-negative adolescents enrolled in the REACH Cohort. The total leukocyte count was significantly reduced in the HIV-positive females in comparison with the HIV-negative females (P < 0.001). There was a reduction in natural killer cells (P < 0.05) in HIV-positive females (mean, 140.6 ± 104.2 x 106 cells/l) in comparison with HIV-negative females (184.3 ± 142.5 x 106 cells/l), whereas no differences were found between the two groups of males. The reduction in the total CD4 cell count in HIV-positive males and females in comparison with the HIV-negative subjects was the consequence of a decrease in both the naive CD4 and memory CD4 components. There was a striking increase in the mean number of CD8 memory cells in HIV-positive compared with HIV-negative adolescents, and a corresponding increase in the percentage of these cells. In contrast, naive CD8 cells were present in increased numbers but their percentage was decreased. Conclusions: These studies of adolescents provide normative data for high-risk healthy adolescents as well as baseline immunologic data for a cohort of ART-naive HIV-positive adolescents. This comparison suggests that this untreated, recently infected group had relatively intact immunologic parameters.

Original languageEnglish (US)
Pages (from-to)1629-1635
Number of pages7
JournalAIDS
Volume13
Issue number13
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Blood Cells
HIV
Therapeutics
HIV Infections
Adolescent Medicine
CD4 Lymphocyte Count
Leukocyte Count
Natural Killer Cells
Flow Cytometry
Acquired Immunodeficiency Syndrome

Keywords

  • Adolescents
  • Antiretroviral naive
  • High-risk adolescents
  • Lymphocyte subsets
  • Surface markers

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Douglas, S. D., Rudy, B., Muenz, L., Moscicki, A. B., Wilson, C. M., Holland, C., ... Weissman, G. (1999). Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. AIDS, 13(13), 1629-1635. https://doi.org/10.1097/00002030-199909100-00005

Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. / Douglas, Steven D.; Rudy, Bret; Muenz, Larry; Moscicki, Anna Barbara; Wilson, Craig M.; Holland, Christie; Crowley-Nowick, Peggy; Vermund, Sten H.; Friedman, L.; Pall, L.; Futterman, Donna C.; Monte, D.; Alovera-DeBellis, M.; Hoffman, Neal D.; Rudy, B.; Schwarz, D.; Tanney, M.; Belzer, M.; Tucker, D.; D'Angelo, L.; Trexler, C.; Townsend-Akpan, C.; Hagler, R.; Peralta, L.; Ryder, G.; Miller, S.; Feroli, K.; Abdalian, S. E.; Foxworth, D.; Green, L.; Sturdevant, M.; Howell, A.; Flynn, P.; Lett, K.; Puga, A.; Cruz; Henry-Reid, L.; Camacho, R.; Bell, M.; Martinez, J.; Johnson, D.; Levin, L.; Geiger, M.; Sawyer, M.; Walls, G.; Birnbaum, J.; Ramnarine, M.; Stanford, P.; Briggs, F.; Holland, C.; Moscicki, A. B.; Murphy, D.; Vermund, S. H.; Booth, R.; Crowley-Nowick, P.; Douglas, S. D.; Wilson, C. M.; Partlow, C.; Hobbs, B.; Ellenberg, J.; Paolinelli, L.; Muenz, L.; Myers, T.; Sheon, A.; Mitchell, Rick; Rogers, A.; Willoughby, A.; Davenny, K.; Smeriglio, V.; Matzen, F.; Lew, J.; Weissman, G.

In: AIDS, Vol. 13, No. 13, 1999, p. 1629-1635.

Research output: Contribution to journalArticle

Douglas, SD, Rudy, B, Muenz, L, Moscicki, AB, Wilson, CM, Holland, C, Crowley-Nowick, P, Vermund, SH, Friedman, L, Pall, L, Futterman, DC, Monte, D, Alovera-DeBellis, M, Hoffman, ND, Rudy, B, Schwarz, D, Tanney, M, Belzer, M, Tucker, D, D'Angelo, L, Trexler, C, Townsend-Akpan, C, Hagler, R, Peralta, L, Ryder, G, Miller, S, Feroli, K, Abdalian, SE, Foxworth, D, Green, L, Sturdevant, M, Howell, A, Flynn, P, Lett, K, Puga, A, Cruz, Henry-Reid, L, Camacho, R, Bell, M, Martinez, J, Johnson, D, Levin, L, Geiger, M, Sawyer, M, Walls, G, Birnbaum, J, Ramnarine, M, Stanford, P, Briggs, F, Holland, C, Moscicki, AB, Murphy, D, Vermund, SH, Booth, R, Crowley-Nowick, P, Douglas, SD, Wilson, CM, Partlow, C, Hobbs, B, Ellenberg, J, Paolinelli, L, Muenz, L, Myers, T, Sheon, A, Mitchell, R, Rogers, A, Willoughby, A, Davenny, K, Smeriglio, V, Matzen, F, Lew, J & Weissman, G 1999, 'Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents', AIDS, vol. 13, no. 13, pp. 1629-1635. https://doi.org/10.1097/00002030-199909100-00005
Douglas, Steven D. ; Rudy, Bret ; Muenz, Larry ; Moscicki, Anna Barbara ; Wilson, Craig M. ; Holland, Christie ; Crowley-Nowick, Peggy ; Vermund, Sten H. ; Friedman, L. ; Pall, L. ; Futterman, Donna C. ; Monte, D. ; Alovera-DeBellis, M. ; Hoffman, Neal D. ; Rudy, B. ; Schwarz, D. ; Tanney, M. ; Belzer, M. ; Tucker, D. ; D'Angelo, L. ; Trexler, C. ; Townsend-Akpan, C. ; Hagler, R. ; Peralta, L. ; Ryder, G. ; Miller, S. ; Feroli, K. ; Abdalian, S. E. ; Foxworth, D. ; Green, L. ; Sturdevant, M. ; Howell, A. ; Flynn, P. ; Lett, K. ; Puga, A. ; Cruz ; Henry-Reid, L. ; Camacho, R. ; Bell, M. ; Martinez, J. ; Johnson, D. ; Levin, L. ; Geiger, M. ; Sawyer, M. ; Walls, G. ; Birnbaum, J. ; Ramnarine, M. ; Stanford, P. ; Briggs, F. ; Holland, C. ; Moscicki, A. B. ; Murphy, D. ; Vermund, S. H. ; Booth, R. ; Crowley-Nowick, P. ; Douglas, S. D. ; Wilson, C. M. ; Partlow, C. ; Hobbs, B. ; Ellenberg, J. ; Paolinelli, L. ; Muenz, L. ; Myers, T. ; Sheon, A. ; Mitchell, Rick ; Rogers, A. ; Willoughby, A. ; Davenny, K. ; Smeriglio, V. ; Matzen, F. ; Lew, J. ; Weissman, G. / Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. In: AIDS. 1999 ; Vol. 13, No. 13. pp. 1629-1635.
@article{8295021ff8914e14b793467c8fc0934c,
title = "Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents",
abstract = "Objective: To examine potential hematologic and immunologic markers for healthy adolescents and for adolescents infected with HIV. Design: The REACH Project (Reaching for Excellence in Adolescent Care and Health) of the Adolescent Medicine HIV/AIDS Research Network (AMHARN) recruits HIV-infected and high-risk HIV-uninfected adolescents, aged at least 13 but less than 19 years. The study evaluates biomedical and behavioral features of HIV infection as observed while under medical care for HIV infection and adolescent health. Methods: Blood samples were collected from HIV-infected and HIV-uninfected subjects at 16 clinical sites. Cell phenotypes were determined using standard single, dual or three-color flow cytometry. Results: This report includes data at enrollment for 94 HIV-positive adolescents who had never received antiretroviral therapy (ART) (mean age, 17.4 ± 1.0 years for males and 16.5 ± 1.3 years for females) and 149 HIV-negative adolescents (mean age, 16.7 ± 1.2 years for males and 16.6 ± 1.2 years for females); this is the antiretroviral therapy-naive subset drawn from 294 HIV-positive and 149 HIV-negative adolescents enrolled in the REACH Cohort. The total leukocyte count was significantly reduced in the HIV-positive females in comparison with the HIV-negative females (P < 0.001). There was a reduction in natural killer cells (P < 0.05) in HIV-positive females (mean, 140.6 ± 104.2 x 106 cells/l) in comparison with HIV-negative females (184.3 ± 142.5 x 106 cells/l), whereas no differences were found between the two groups of males. The reduction in the total CD4 cell count in HIV-positive males and females in comparison with the HIV-negative subjects was the consequence of a decrease in both the naive CD4 and memory CD4 components. There was a striking increase in the mean number of CD8 memory cells in HIV-positive compared with HIV-negative adolescents, and a corresponding increase in the percentage of these cells. In contrast, naive CD8 cells were present in increased numbers but their percentage was decreased. Conclusions: These studies of adolescents provide normative data for high-risk healthy adolescents as well as baseline immunologic data for a cohort of ART-naive HIV-positive adolescents. This comparison suggests that this untreated, recently infected group had relatively intact immunologic parameters.",
keywords = "Adolescents, Antiretroviral naive, High-risk adolescents, Lymphocyte subsets, Surface markers",
author = "Douglas, {Steven D.} and Bret Rudy and Larry Muenz and Moscicki, {Anna Barbara} and Wilson, {Craig M.} and Christie Holland and Peggy Crowley-Nowick and Vermund, {Sten H.} and L. Friedman and L. Pall and Futterman, {Donna C.} and D. Monte and M. Alovera-DeBellis and Hoffman, {Neal D.} and B. Rudy and D. Schwarz and M. Tanney and M. Belzer and D. Tucker and L. D'Angelo and C. Trexler and C. Townsend-Akpan and R. Hagler and L. Peralta and G. Ryder and S. Miller and K. Feroli and Abdalian, {S. E.} and D. Foxworth and L. Green and M. Sturdevant and A. Howell and P. Flynn and K. Lett and A. Puga and Cruz and L. Henry-Reid and R. Camacho and M. Bell and J. Martinez and D. Johnson and L. Levin and M. Geiger and M. Sawyer and G. Walls and J. Birnbaum and M. Ramnarine and P. Stanford and F. Briggs and C. Holland and Moscicki, {A. B.} and D. Murphy and Vermund, {S. H.} and R. Booth and P. Crowley-Nowick and Douglas, {S. D.} and Wilson, {C. M.} and C. Partlow and B. Hobbs and J. Ellenberg and L. Paolinelli and L. Muenz and T. Myers and A. Sheon and Rick Mitchell and A. Rogers and A. Willoughby and K. Davenny and V. Smeriglio and F. Matzen and J. Lew and G. Weissman",
year = "1999",
doi = "10.1097/00002030-199909100-00005",
language = "English (US)",
volume = "13",
pages = "1629--1635",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents

AU - Douglas, Steven D.

AU - Rudy, Bret

AU - Muenz, Larry

AU - Moscicki, Anna Barbara

AU - Wilson, Craig M.

AU - Holland, Christie

AU - Crowley-Nowick, Peggy

AU - Vermund, Sten H.

AU - Friedman, L.

AU - Pall, L.

AU - Futterman, Donna C.

AU - Monte, D.

AU - Alovera-DeBellis, M.

AU - Hoffman, Neal D.

AU - Rudy, B.

AU - Schwarz, D.

AU - Tanney, M.

AU - Belzer, M.

AU - Tucker, D.

AU - D'Angelo, L.

AU - Trexler, C.

AU - Townsend-Akpan, C.

AU - Hagler, R.

AU - Peralta, L.

AU - Ryder, G.

AU - Miller, S.

AU - Feroli, K.

AU - Abdalian, S. E.

AU - Foxworth, D.

AU - Green, L.

AU - Sturdevant, M.

AU - Howell, A.

AU - Flynn, P.

AU - Lett, K.

AU - Puga, A.

AU - Cruz,

AU - Henry-Reid, L.

AU - Camacho, R.

AU - Bell, M.

AU - Martinez, J.

AU - Johnson, D.

AU - Levin, L.

AU - Geiger, M.

AU - Sawyer, M.

AU - Walls, G.

AU - Birnbaum, J.

AU - Ramnarine, M.

AU - Stanford, P.

AU - Briggs, F.

AU - Holland, C.

AU - Moscicki, A. B.

AU - Murphy, D.

AU - Vermund, S. H.

AU - Booth, R.

AU - Crowley-Nowick, P.

AU - Douglas, S. D.

AU - Wilson, C. M.

AU - Partlow, C.

AU - Hobbs, B.

AU - Ellenberg, J.

AU - Paolinelli, L.

AU - Muenz, L.

AU - Myers, T.

AU - Sheon, A.

AU - Mitchell, Rick

AU - Rogers, A.

AU - Willoughby, A.

AU - Davenny, K.

AU - Smeriglio, V.

AU - Matzen, F.

AU - Lew, J.

AU - Weissman, G.

PY - 1999

Y1 - 1999

N2 - Objective: To examine potential hematologic and immunologic markers for healthy adolescents and for adolescents infected with HIV. Design: The REACH Project (Reaching for Excellence in Adolescent Care and Health) of the Adolescent Medicine HIV/AIDS Research Network (AMHARN) recruits HIV-infected and high-risk HIV-uninfected adolescents, aged at least 13 but less than 19 years. The study evaluates biomedical and behavioral features of HIV infection as observed while under medical care for HIV infection and adolescent health. Methods: Blood samples were collected from HIV-infected and HIV-uninfected subjects at 16 clinical sites. Cell phenotypes were determined using standard single, dual or three-color flow cytometry. Results: This report includes data at enrollment for 94 HIV-positive adolescents who had never received antiretroviral therapy (ART) (mean age, 17.4 ± 1.0 years for males and 16.5 ± 1.3 years for females) and 149 HIV-negative adolescents (mean age, 16.7 ± 1.2 years for males and 16.6 ± 1.2 years for females); this is the antiretroviral therapy-naive subset drawn from 294 HIV-positive and 149 HIV-negative adolescents enrolled in the REACH Cohort. The total leukocyte count was significantly reduced in the HIV-positive females in comparison with the HIV-negative females (P < 0.001). There was a reduction in natural killer cells (P < 0.05) in HIV-positive females (mean, 140.6 ± 104.2 x 106 cells/l) in comparison with HIV-negative females (184.3 ± 142.5 x 106 cells/l), whereas no differences were found between the two groups of males. The reduction in the total CD4 cell count in HIV-positive males and females in comparison with the HIV-negative subjects was the consequence of a decrease in both the naive CD4 and memory CD4 components. There was a striking increase in the mean number of CD8 memory cells in HIV-positive compared with HIV-negative adolescents, and a corresponding increase in the percentage of these cells. In contrast, naive CD8 cells were present in increased numbers but their percentage was decreased. Conclusions: These studies of adolescents provide normative data for high-risk healthy adolescents as well as baseline immunologic data for a cohort of ART-naive HIV-positive adolescents. This comparison suggests that this untreated, recently infected group had relatively intact immunologic parameters.

AB - Objective: To examine potential hematologic and immunologic markers for healthy adolescents and for adolescents infected with HIV. Design: The REACH Project (Reaching for Excellence in Adolescent Care and Health) of the Adolescent Medicine HIV/AIDS Research Network (AMHARN) recruits HIV-infected and high-risk HIV-uninfected adolescents, aged at least 13 but less than 19 years. The study evaluates biomedical and behavioral features of HIV infection as observed while under medical care for HIV infection and adolescent health. Methods: Blood samples were collected from HIV-infected and HIV-uninfected subjects at 16 clinical sites. Cell phenotypes were determined using standard single, dual or three-color flow cytometry. Results: This report includes data at enrollment for 94 HIV-positive adolescents who had never received antiretroviral therapy (ART) (mean age, 17.4 ± 1.0 years for males and 16.5 ± 1.3 years for females) and 149 HIV-negative adolescents (mean age, 16.7 ± 1.2 years for males and 16.6 ± 1.2 years for females); this is the antiretroviral therapy-naive subset drawn from 294 HIV-positive and 149 HIV-negative adolescents enrolled in the REACH Cohort. The total leukocyte count was significantly reduced in the HIV-positive females in comparison with the HIV-negative females (P < 0.001). There was a reduction in natural killer cells (P < 0.05) in HIV-positive females (mean, 140.6 ± 104.2 x 106 cells/l) in comparison with HIV-negative females (184.3 ± 142.5 x 106 cells/l), whereas no differences were found between the two groups of males. The reduction in the total CD4 cell count in HIV-positive males and females in comparison with the HIV-negative subjects was the consequence of a decrease in both the naive CD4 and memory CD4 components. There was a striking increase in the mean number of CD8 memory cells in HIV-positive compared with HIV-negative adolescents, and a corresponding increase in the percentage of these cells. In contrast, naive CD8 cells were present in increased numbers but their percentage was decreased. Conclusions: These studies of adolescents provide normative data for high-risk healthy adolescents as well as baseline immunologic data for a cohort of ART-naive HIV-positive adolescents. This comparison suggests that this untreated, recently infected group had relatively intact immunologic parameters.

KW - Adolescents

KW - Antiretroviral naive

KW - High-risk adolescents

KW - Lymphocyte subsets

KW - Surface markers

UR - http://www.scopus.com/inward/record.url?scp=18544393336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544393336&partnerID=8YFLogxK

U2 - 10.1097/00002030-199909100-00005

DO - 10.1097/00002030-199909100-00005

M3 - Article

VL - 13

SP - 1629

EP - 1635

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -